metastatic breast cancer

Research Reports

Potential Cost Effectiveness of FES-PET to Determine Estrogen Receptor Status in Metastatic Breast Cancer in the United States

10/20/2021

Poorni M. Manohar, MD

Hannah M. Linden, MD

Josh A. Roth, PhD, MHA

Poorni M. Manohar, MD, et al assessed the potential value of 18-F 16 alpha-fluoroestradiol positron emission tomography (FES-PET) vs biopsy to determine estrogen receptor status and guide therapy selection in metastatic breast cancer.

Poorni M. Manohar, MD, et al...

10/20/2021

Journal of Clinical Pathways

Research Reports

Effectiveness of Eribulin in Metastatic Breast Cancer Patients With Poor Prognostic Indicators in the United States

06/21/2021

Sarah S Mougalian, MD

Jingchuan Zhang, PhD

Talia Miller, MSW, MPH

Marjorie E Zettler, PhD, MPH

Bruce A Feinberg, DO

A retrospective real-world study demonstrates the clinical effectiveness of eribulin in subgroups of MBC patients with poor prognostic characteristics, when used in accordance with the approved US indication.

A retrospective real-world study...

06/21/2021

Journal of Clinical Pathways